ASLV Vector System Split-Packaging SIN-LTR Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current viral vector systems, particularly those based on Avian Sarcoma Leukosis Virus (ASLV), face challenges in minimizing the risk of recombination to form replication-competent retroviruses and insertion mutagenesis, which can activate neighboring genes, while also requiring high titer production and efficient transgene expression for clinical applications.
Innovation Solution
A split-packaging system using a viral vector with a self-inactivating 3'-LTR (SIN-LTR) and helper plasmids encoding gag-pol and envelope proteins, optimized for codon usage in human cells, to produce non-replicating viral particles with reduced promoter and enhancer activity, minimizing genomic activation and ensuring high titer and stable transgene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a full-length ASLV plasmid system is used with intact LTRs for replication-competent retrovirus production, then viral particle production is achieved, but the risk of recombination to form replication-competent retroviruses increases
Solution Approach 1:
The packaging system is divided into separate functional components: a SIN vector plasmid containing only the transgene and LTRs, and a helper plasmid containing all viral structural genes (gag, pol, env). This segmentation prevents recombination because the vector plasmid lacks the structural genes necessary to form replication-competent retroviruses, even though viral particles are produced through trans-complementation from the helper plasmid.
Solution Approach 2:
The replication competence is extracted from the vector plasmid and placed solely in the helper plasmid. The vector plasmid is stripped of all viral structural coding sequences, retaining only the essential LTRs and transgene. This extraction eliminates the risk that the vector itself could generate replication-competent retroviruses, as it contains no viral structural genes.
2Productivity
If intact LTRs with functional U3 regions are used in the vector, then viral particle production is enhanced, but the risk of insertional mutagenesis and activation of neighboring genes increases
Solution Approach 1:
The harmful promoter and enhancer activities are extracted from the vector plasmid by deleting the U3 region of the LTR. Only the minimal LTR structure containing the polyadenylation signal is retained in the vector, while all transcriptional activation functions are removed. This prevents the vector from activating neighboring genes upon integration, as the LTR lacks functional promoter and enhancer elements.
Solution Approach 2:
The LTR in the vector plasmid is modified to have different functional properties at different locations: the 5' LTR retains the polyadenylation signal (essential for viral RNA processing), while the 3' LTR U3 region is deleted to remove promoter and enhancer activities. This local differentiation of functional elements allows the vector to produce viral particles without causing insertional mutagenesis.
3Object-affected harmful factors
If the U3 region is completely deleted from the LTR to eliminate promoter activity, then insertional mutagenesis risk is reduced, but viral particle production may be compromised
Solution Approach 1:
The helper plasmid acts as an intermediary that provides all necessary viral structural proteins (gag, pol, env) through transient expression in packaging cells. This intermediary system allows the vector plasmid to lack structural genes while still producing functional viral particles, as the helper plasmid supplies the missing components through trans-complementation.
Solution Approach 2:
The helper plasmid serves multiple functions simultaneously: it provides viral structural genes, supplies packaging signals, and enables high-titer viral particle production. This multi-functionality allows the vector plasmid to be simplified to only contain the transgene and minimal LTR elements, separating the functions of viral particle production from transgene carriage.
Data Source
Figure 1~4
Figure 5
Figure 6
AI summary
The application provides a viral self-inactivating (SIN) vector based on the avian sarcoma leuosis virus (ASLV) and a split-packaging system which comprises, besides the SIN vector, a first helper plasmid for the expression of the viral fusion protein gag-pol and a second helper plasmid for the expression of the retroviral envelope protein (env). The first and the second helper plasmid, present for example in a packaging cell line or transiently transfected, serve for generating nonreplicating (RCR-incompetent) viral particles which comprise RNA with an SIN-LTR according to the invention at the 3' terminus, where the RNA may have a therapeutically active segment which is referred to for example as a transgene. This 3' SIN LTR comprises an extensive deletion of the U3 region, which is copied into the 5' LTR during reverse transcription. Furthermore, all coding regions of ASLV and the retroviral splice donor site are removed in the SIN vector.